Aurora Cannabis Submits Regular SEC Filing and Reports

LOS ANGELES- Aurora Cannabis Inc. a  the medicinal chemicals and botanical products industry, has filed a Form 6-K report with the U.S. Securities and Exchange Commission (SEC) for July. The Edmonton, Alberta-based company submitted this routine filing as a foreign private issuer, including a news release dated July 9, 2024, as an exhibit.

The filing, dated July 11, 2024, confirms Aurora Cannabis’s compliance with the SEC Act of 1934. CEO Miguel Martin signed the report, ensuring the accuracy and completeness of the submission. The company’s executive office is located in Edmonton, with a mailing address in Vancouver, British Columbia.

While the specific contents of the news release were not disclosed in the filing announcement, the Form 6-K submission reflects Aurora Cannabis’s commitment to regulatory compliance and transparency for investors.

In recent developments, Aurora Cannabis reported its most successful fiscal year, with a 21% increase in net revenue and a 49% adjusted gross margin. This growth is largely due to its focus on the medical cannabis market in Canada and Australia. Additionally, the company appointed Simona King as their new CFO, who brings extensive experience from the pharmaceutical and biotech sectors.

Aurora’s international medical cannabis business grew by nearly 40% in the fourth quarter, enhancing its global market position. Despite a decrease in consumer cannabis net revenue, falling to $10.2 million from $14.5 million, the company remains optimistic about its strategic shift towards the high-margin international market.

Looking ahead, Aurora Cannabis anticipates continued growth, particularly following its investment in VIVO and expansion plans in Europe and Australia. The company aims to achieve positive free cash flow by the end of 2024, navigating regulatory environments and leveraging its expertise in medical cannabis.